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Prenylated flavonoids derived from Hops (Humulus lupulus) activate the γ-aminobutyric acid (GABA) type A receptors through positive and negative modulation. Currently, these 
compounds’ binding site at the different GABAAR subtypes is still unknown.  
Molecular interactions of several prenylated flavonoids were investigated at different GABAAR binding sites. The focus was on the receptor subtypes containing αβγ and αβδ subunits and the aim was to identify the most likely binding site for the prenylflavonoids by studying the relation between a ligand structure and the residues defining its putative pocket and the ligand’s calculated binding affinity. 
Available GABAAR crystal structures were obtained from the Protein Data Bank, and a 
comparative model of the α6β3δ receptor subtype was built using the MODELLER software. The compounds were docked at the putative binding sites of the studied GABAAR subtype structures with the GLIDE tool of the Maestro molecular modeling package. An estimate of the free energy of binding was calculated with the Prime/MMGBSA tool of Maestro for all the docked receptor-ligand complexes. 
The obtained results suggest that prenylflavonoids may bind to more than one pocket in the extracellular domain of the studied GABAAR subtypes. It was not possible to distinguish high affinity binding sites from low affinity binding sites as the docking results varied for each compound in the studied pockets. Discrepancy in results is likely caused by modeling binding site without knowing the correct conformations of the side chains forming the pockets. Based on the modelled α6β3δ subtype, β3δ interface may be the most likely binding site for the hops compounds. To determine the binding of the prenylated flavonoids most accurately, experimental structure determination by X-ray crystallography could be attempted. 
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1.Scientific background of the research project 
1.1. GABAA receptor 
Class A γ-aminobutyric acid (GABA) receptors are abundant in mammalian central 
nervous system(CNS), but can also be found in other types of tissues, where they are most 
commonly located postsynaptically (Yocum et al., 2016). They represent the major 
inhibitory receptors in human brain, potentiated by the endogenous neurotransmitter 
GABA. The GABAA receptors get activated and change their conformation after GABA 
is bound, which results in channel opening and permeation of both chloride and 
bicarbonate ions. Consequently, the cell membrane becomes hyperpolarized and inhibits 
the possibility for neuronal transmission (Uusi-Oukari and Korpi, 2010; Miller and 
Aricescu, 2014). GABA-induced inhibition of neuronal excitation can last for 
milliseconds or have a longer time range. Postsynaptic receptors confer the short, 
millisecond-lasting inhibition, whereas extrasynaptically located GABAA receptors 
(GABAARs) mediate long-term inhibition(Sigel and Steinmann, 2012).  
Architecture of these cysteine (Cys)-loop type of receptors includes multiple subunits, 
usually assembled in a pentameric form, with a variety of isoform compositions (Olsen 
et al., 2009). Subunits are termed α1 to 6, β1 to 3, γ1 to 3, δ, ε, θ, π and ρ1 to 3. All the 
subunits forming the receptors are placed in the cell membrane in such a manner that 
they have an extracellular, transmembrane and intracellular domain. The extracellular 
part of each subunit starts with the N-terminus that continues into alpha helices, beta 
sheets and the Cys-loops characteristic for this receptor family. Subunits then permeate 
the cell membrane where they form four alpha-helical M transmembrane domains (M1-
M4). The largest loop connecting M3 and M4 domains, located inside the cell plays an 
important role in phosphorylation and receptor regulation. M4 domain finally exits the 
lipid bilayer and ends up in the C-terminus back in the extracellular side of the membrane 
(Figure 1a). The extracellular domain of the receptor is where GABA and benzodiazepine 
(BZD) agonists bind, between the beta sheets of two different subunits (Figure 1b and 1c) 
(Clayton et al., 2007; Uusi-Oukari et al., 2010).  
The beta sheets of a single subunit assemble into a beta-sandwich form that is comprised 
of ten β-strands. Numbering of the beta strands starts at the N-terminus and ends at the 
C-terminus, whereas the annotation of the loops (A to F) begins at the C-terminus and 
ends at the N-terminus. Loops A to C belong to the outer sheet and they are the principal 
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plus (+) side of a subunit, while the minus (−) complementary side is comprised of D to 
F loops. The details of the architecture are presented in Figure 1d. These sheets are named 
the outer and the inner sheet, meaning that the outer one is localized abluminally and the 
inner one is luminal (Ernst et al., 2005). 
The principal receptor isoform, present in the human brain, is assembled from two α1 and 
two β2 subunits and one γ2 subunit (Figure 1c). This subunit composition corresponds to 
the synaptic form of the receptor and generates a fast receptor response and a short 
inhibition. On the other hand, extra synaptic GABAARs are believed to contain the δ 
subunit commonly paired with the α4 or α6 subunit (Yakoub et al., 2018). 
The subunits that form GABA receptors are highly homologous within the same class, 
and show relatively good homology among the various subclasses, 60% to 80% and 30% 
to 40%, respectively (Clayton et al., 2007). Various isoforms of the homologous subunits 
are important for they define the properties of the receptor, such as ligand affinity, channel 
opening and conductivity (Cossart et al., 2005). Majority of GABAARs are assembled 
from five subunits, forming heteropentamers, with the  receptor subtype being the 
most abundant one. The arrangement of this receptor subtype, as well as that of the 
 subtype, that is also studied in this project, is shown to be 
−−−− (Puthenkalam et al., 2016). X-ray structure determination shows that 
possible interfaces between the subunits in  receptor types are 
+− +− +− +− (Tretter et al., 1997; Baumann et al., 2007;  Zhu et al. 2018; 
Masiulis et al. 2019). It is less clear how  subunit-containing receptors are arranged; 
hence the exact interface types are less known. Some of the arrangements in this receptor 
subtype are determined (Lee et al., 2016), however, no crystal structure of a GABAAR 
heteropentamer containing the  subunit is released to date. 
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Figure 1. a) Topology of a single subunit of the GABAAR (cartoon representation). Alpha 
helices are colored red, beta sheets yellow and loops are shown in green. b) Side view of 
GABAAR architecture with a ligand pocket marked with green and blue spheres that 
represent the residues of the two subunits that form the BZD binding pocket. c) Top view 
of the receptor (surface presentation) shows the arrangement of the subunits and the 
binding sites of GABA, benzodiazepine (BZD) and flumazenil. In the place of γ subunit, 
δ may be present (PDB ID: 6D6U). d) Topology of a single GABAAR subunit. The beta 
strands are depicted as cartoon representation and numbered from 1 to 10, starting at the 
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N-terminus. Loops from A to C, that are part of the principal (+) side are annotated in red 
and the complementary (− side) loops D to F are annotated in blue (PDB ID: 4COF). 
 
In addition to binding GABA, these receptors are drug targets for compounds that possess 
sedative and anxiolytic effects. Furthermore, there is evidence from the literature that 
reduced GABAAR activity results in disorders such as seizures and epileptic 
encephalopathies (Macdonald et al., 2004).  
Drug classes such as benzodiazepines (BZDs), β-carbolines, Z-drugs (zopiclone, 
zolpidem) as well as pyrazolo quinolinones exert their effects by allosterically modulating 
the GABAARs. On the other hand, a broad range of side effects is believed to result from 
the Cl- channel gate altering. It is believed that the difference in the type of the effect 
caused by the drugs may result from the subunit type and the binding pocket localization 
involved in the receptor-ligand interaction. For example, experimental evidence shows 
that sedative effects are mediated by α1-subunit and this subunit type is also being targeted 
for sedative and hypnotic effects. On the other hand, memory-affecting receptors are 
those that include α5 in their structure, while effects such as anxiolysis are displayed in 
the α2 and α3 subunit containing GABAARs (Rudolph et al., 1999).  
GABA binds to the extracellular domain (ECD) of the receptor, to the classical 
neurotransmitter binding site. BZDs bind at sites in close proximity to that of GABA, 
called the high-affinity benzodiazepine binding site. GABA is known to bind to the β2/α1 
pocket and BZDs at the α1/γ2 interface. BZD antagonist, flumazenil binds at a region close 
to the GABA pocket, as well. On the other hand, receptor isoforms that contain α4 or α6 
subunits were shown to be BZD insensitive (Sigel et al., 2018). Other drugs elicit their 
effects by binding to different domains and subunit interfaces. For example, propofol and 
volatile anesthetics bind closer to the transmembrane domain (Figure 2). Allosteric 
binding sites that are not canonical GABA binding sites seem to be a good target for 
optimizing drug selectivity. Identification and design of highly selective drugs that would 
target GABAAR is an ongoing issue. However, the fact that the binding pocket-forming 
subunits such as α2, α3 and γ2, γ3 are too similar to each other hampers the precise design 
of high specificity compounds or those that would have well defined functional selectivity 
(Sigel et al., 2018). 
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Figure 2. Binding sites of some clinically significant drugs on GABAAR receptor (PDB 
ID: 4COF) 
1.2. Flavonoids and GABAAR modulation 
In herbal medicine flavonoid compounds derived from hops (Humulus lupulus) are used 
as sleeping aid (Zanoli and Zavatti, 2008) and they also show potential neuroactivity such 
as alleviating anxiety disorders and affecting the cognition process (Wang et al., 2007, 
2011; Zhang et al., 2012; Spencer, 2008, 2009). It is likely that these effects are mediated 
via GABAA receptors, the main inhibition site in the brain, via allosteric (or possibly even 
direct) modulation of the BDZ binding site (Sieghart, 1995; de Oliveira et al., 2018). 
Prenylflavonoids in hops extracts, display a wide range of biological activities that are 
beneficial to human health. The most significant prenylflavonoids are xanthohumol (XN), 
isoxanthohumol (IXN), and 8-prenylnaringenin (8PN) (Karabín et al., 2016). Evidence 
from the literature indicates that XN elicited GABAergic effects by modulating 
GABAARs (Aoshima et al., 2006; Sahin et al., 2016). Recently published data regarding 
the aforementioned hops compounds reveals that prenylflavonoid modulation of the 
GABAAR is flumazenil insensitive. This means that the site of action of these compounds 
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is likely not the same as that of flumazenil (+−). Nonetheless, there is some evidence 
that flavonoids could act through the flumazenil-sensitive site as well (Johnston et al., 
2015). The tested hops compounds have the highest affinity for the α6β3δ interface 
(Benkherouf et al., 2019), however, the exact site of action remains unknown.  
This study aims to locate the potential binding sites for hops-derived compounds XN, 
IXN, 8PN and 6-prenylnaringenin (6PN) at GABAARs and to investigate the interactions 
between the ligands and the GABAAR receptor subtypes composed of αβγ and αβδ 
subunits.  
Furthermore, this study focuses on identifying the most likely binding site for the 
prenylflavonoids through studying the relation between the residues that form a putative 
binding pocket and the ligand that was docked in it. Additionally, we aim to describe the 
molecular properties of prenylflavonoids that are important for receptor-ligand 
interaction and that lead to preference for the binding pocket location. For this, several 
subunit interfaces are studied. Figure 3 shows the binding pocket where flumazenil was 
crystallized () and the most important interactions of flumazenil and the residues that 
form the binding site. Despite the fact that preliminary docking results at the principal 
isoform (α1β2γ2) show that prenylflavonoids fit well into the flumazenil-binding pocket, 
this is not the subunit interface that we hypothesize to be the main binding site for them. 
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Figure 3. Binding pocket of the GABAA receptor isoform in which flumazenil was 
crystallized (PDB ID: 6D6U). Carbon atoms of flumazenil are colored yellow. Subunits 
α1 and γ2 that form the pocket are colored pink and cyan, respectively (all oxygen atoms 
are in red, nitrogen atoms in blue). The most important interactions are π-π stacking 
interactions between the diazepine ring of flumazenil and tyrosine 210 and polar 
(hydrogen bonding) interactions of flumazenil with threonine 142 and histidine 102. Polar 
interactions are shown as dotted yellow lines. 
Despite eliciting GABAergic effects, it is not likely that prenylflavonoids bind to the 
canonical GABA site on the receptor. Instead, it is likely that binding happens either 
closer to the transmembrane domain or at another subunit interface that might have 
similar properties to the flumazenil-binding pocket. This we assume based on the sizes of 
the molecules (Figure 4) and the ligand-binding pockets of GABA and flumazenil. 
Flumazenil binds closer to the ECD, and it has some structural similarity to the studied 
hops compounds; hence, we hypothesize that they are likely to bind at similar pockets. 
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Figure 4. 2D structure of hops-derived compounds, xanthohumol, 8-prenylnaringenin, 
isoxanthohumol and 6-prenylnaringenin, as well as the BZD antagonist flumazenil and 
endogenous neurotransmitter GABA. 
The ultimate goal of this project is to map the GABAA receptor subtype properties that 
mediate the sedative effects of the hops-derived compounds. This would also contribute 
to understanding the role of different subunits involved in various GABAergic actions in 
the CNS. Successful determination of the exact site to which our compounds bind would 
not only help define important binding properties of the molecules but could also help in 
the rational drug design of more selective GABAAR ligands that would be devoid of the 
unwanted effects caused by drugs that act via BZD site such as anxiety, sedation, 
tolerance and addiction. Additionally, for future prospects, searching for homologous 
compounds to the tested prenylflavonoid ligands may help identify potential new drugs 
targeting GABAA receptor and these compounds could then be tested experimentally. In 
sum, this research project may not only help identify relevant characteristics of our 
compounds, but potentially introduce new grounds for creating drugs that possess 
desirable GABAergic effects and at the same time are do not exert the adverse effects 
caused by potentiating GABAA receptor activity. 
 
  
GABA 
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2. Results 
2.1. Homology modeling 
The modeling alignments obtained for the subunits  and  are presented in Figures 5 
and 6. The template proteins were selected based on the number of positives and species 
(Homo sapiens) from the Protein BLAST search results (see the Appendix). The BLAST 
search showed that the B chain of the crystal structure PDB ID: 6D6T and the A chain of 
the crystal structure PDB ID: 6A96 were the most suitable templates for the  subunit, 
while the A chain of the crystal structure PDB ID: 6D6T and the A chain of the crystal 
structure PDB ID: 4COF were the most preferable sequences for creating the 3D model 
of the  subunit. 
  
 
 
 
 
 
 
 
 
 
 
Figure 5. Multiple sequence alignment for the subunit  that was used for creating the 
homology model. 
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Figure 6. Multiple sequence alignment for the subunit  that was used for creating the 
homology model. 
The final models for both subunits were selected based on the lowest DOPE-score and 
visual inspection. Results from the created subunit models are presented in the Figure 7. 
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Figure 7. a) Scoring of the created models. In both subunits the lowest DOPE score model 
was selected. b) Scoring of the final GABAAR subtype. The lowest DOPE score model 
was selected for further studies as it seemed the most suitable after visual inspection. 
The full receptor model of the  subtype was then created by employing the Multiple 
chain model alignment in a similar manner as with the subunits (Sali and Blundell, 1993).  
2.2. Molecular dynamics simulations 
During the molecular dynamics (MD) simulation the total potential energy of both full 
receptor model and the binding sites model remained stable (Figure 7). Prior to the MD 
simulations of the receptor models there was 98.0% and 2.0% residues in favored and 
allowed regions, respectively, for the full receptor model and 98.0% and 2.0% residues 
in the favored and allowed regions, respectively, for the binding sites model. There were 
no residues present in the outlier region for the binding sites model prior to the MD 
simulation, while for the full receptor model there were 12 residues present in the outlier 
region. After the MD simulations were completed the Ramachandran analysis of the 
structures showed 93.2% and 6.4% residues in favored and in allowed regions, 
respectively, for the binding sites model and 94.4% and 5% for the full receptor model. 
The first one had four residues (0.4%) in the outlier regions, and the latter had six residues 
12  
(0.4%) in the outlier regions. However, neither of those residues were part of any of the 
studied binding pockets (Figure 8). The crystal structures 4COF and 6D6U did not have 
any residues in the outlier region and the percentage of the residues I favored and allowed 
regions in both crystals were 98.0% and 2.0%, respectively. 
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Figure 8. Ramachandran plot evaluation done by RAMPAGE after and prior to the MD 
simulations. 
Analysis of the created full GABAAR model indicated that there may be an issue 
regarding the stability of the structure. The radius of gyration describes how compact a 
protein is and the results of MD simulation suggest that there was an increase in the radius 
of gyration value for the created full receptor model (Figure 9). 
Binding sites model 
Full receptor model 
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Figure 9. Radius of gyration of the full GABAAR model compared to the template (PDB 
ID: 4COF).  
2.3. Docking 
Docking was performed with no constraints and the best docking poses were selected 
based on the estimated free energy of binding (Prime/MMGBSA), Glide XP docking 
score, Induced Fit g-score and visual assessment. The best poses for the ligands were 
considered to be those that included most of the reported favorable interactions for the 
flavonoids (Renard et al., 1999; Huang et al., 2001). Such interactions include the 
presence of π-π stacking, salt bridges, hydrogen bonds and π-cation interactions between 
prenylflavonoids and the binding pocket residues. Flumazenil, bicuculline and CGS-9885 
were used as reference structures in terms of the Prime/MMGBSA energies and the 
docking scores in their respective binding pockets.  
Results obtained from docking at the potential binding sites are shown in Tables 1, 5, 7 
and 8. The residues that are most likely to form strong interactions with the studied 
ligands are displayed in Tables 2, 3, 4 and 6. 
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2.4. Docking performed in the  receptor isoform 
The most favorable free energy of binding was predicted for 6PN in the 
+− and+− pockets while XN seemed to fit better than the other compounds in 
the −+ pocket (Table 1). 8PN had the least favorable calculated MMGBSA values in 
all the three putative pockets that were investigated in this structure. MMGBSA of 
flumazenil in its experimental binding site, prior to induced fit docking was -62.218. 
Table1. Docking scores and estimated binding free energies in different binding pockets 
of the crystal structure of GABAAR  subtype (PDB ID: 6D6U). 
Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) XP g-score 
6-prenylnaringenin -71.13 -8.255 
8-prenylnaringenin -50.65 -9.824 
Xanthohumol -45.33 -6.139 
Isoxanthohumol -63.00 -8.898 
Flumazenil -64.94 -6.882 
 
Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) XP g-score 
6-prenylnaringenin -67.11 -8.255 
8-prenylnaringenin -60.74 -9.824 
Xanthohumol -61.74 -6.139 
Isoxanthohumol -60.97 -8.898 
CGS-9895 -69.64 -6.882 
 
Binding site +− 
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Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -50.65 -6.013 
8-prenylnaringenin -50.58 -6.278 
Xanthohumol -66.97 -10.146 
Isoxanthohumol -64.54 -7.655 
 
Hydrogen bonds involved in receptor-ligand interactions at the +− and 
+−  pockets in this structure were most commonly formed with histidine, serine and 
threonine, while tyrosine and phenylalanine seemed to be mostly involved in the π-π 
stacking interactions. At the +− putative binding pocket asparagine was mostly the 
residue participating hydrogen bonds (Tables 2, 3 and 4). 
Table 2. Residues interacting with the docked compounds at the  binding pocket of 
 GABAAR subtype 
Compound Subunit  Subunit  
6-prenylnaringenin His102, Ser159, Ser205, Ser206, Tyr160, Tyr210 Thr142, Glu189 
Xanthohumol His102, Ser159, Thr207 Asp56, Thr142 
Isoxanthohumol His102, Ser159, Tyr160, Tyr210 Thr142 
8-prenylnaringenin Ala101, His102, Ser159, Phe100, Tyr210 Met57, Tyr58 
Flumazenil Ala161, Thr207, Tyr210 Thr142 
 
The residues that are predicted to form strong interactions, such as hydrogen bonds, 
hydrophobic interaction/van der Waals interactions or − stacking, with 
prenylflavonoids in the binding site between 1 and  subunits at the  receptor 
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subtype, were tyrosine 210, histidine 102, serine 159 and threonine 207 ( subunit) and 
threonine 142 (2 subunit) and they are presented in bold. 
Table 3. Residues interacting with the docked compounds at the binding pocket of 
 GABAAR subtype 
Compound Subunit α1 Subunit β2 
6-prenylnaringenin Gln204, His102, Phe100, Ser159, Ser205, Ser206, Tyr160, Tyr210 Tyr62 
8-prenylnaringenin His102, Lys156, Phe100, Tyr210 Tyr62 
Xanthohumol His102, Lys156, Tyr210 Ala45, Tyr62 
Isoxanthohumol His102, Phe100, Tyr210 Tyr62 
CGS-9895 His102, Ser206 Tyr62 
 
The residues that are predicted to form strong interactions with prenylflavonoids in the 
binding site between  and  subunits at the  receptor subtype, were tyrosine 210, 
histidine 102, lysine 156 and phenylalanine 100 ( subunit) and tyrosine 62 ( subunit). 
Table 4. Residues interacting with the docked compounds at the binding pocket of 
 GABAAR subtype 
Compound Subunit 2 Subunit  
6-prenylnaringenin Asp43, Lys180, Tyr62 Asn115 
8-prenylnaringenin Thr176 Ser171, Tyr172 
Xanthohumol Asp43, Ile44, Tyr62 Arg114, Thr215, Ser217 
Isoxanthohumol Asp43 Glu168 
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The residues that are predicted to form strong interactions with prenylflavonoids in the 
binding site between  and  subunits at the  receptor subtype, were asparagine 
43, tyrosine 62 ( subunit). It was not possible to determine what residues from the 
 subunit would make strong interactions at this interface. 
2.5. Docking results from the α1β3γ2 crystal structure 
Results from the docking studies at the α1β3γ2 isoform crystal were somewhat different at 
the two  interfaces. From all the hops compounds, IXN had the highest values at the 
interface of A and B chains interface, whereas 8PN seemed to have the best scores at the 
interface of D and E chains. 6-prenylnaringenin had the least desirable docking results in 
both studied pockets (Table 5). Bicuculline had the best scores in both pockets. Residues 
that were most reoccurring in the formation of interactions with the hops compounds at 
these sites are shown in Table 6. 
Table 5. Docking scores and estimated binding free energies in different binding pockets 
of the crystal structure of GABAAR  subtype (PDB ID: 6HUK). 
Binding site +−  (AB chains) 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) XP g-score 
6-prenylnaringenin -46.36 -8.412 
8-prenylnaringenin -49.76 -8.486 
Xanthohumol -47.75 -6.807 
Isoxanthohumol -54.65 -8.727 
Bicuculline -66.33 -10.072 
 
Binding site +− (DE chains) 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) XP g-score 
6-prenylnaringenin -32.57 -6.751 
8-prenylnaringenin -36.47 -6.906 
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Xanthohumol -36.28 -5.852 
Isoxanthohumol -36.21 -6.767 
Bicuculline -53.74 -9.317 
 
Table 6. Residues interacting with the docked compounds at the binding pocket of 
 GABAAR subtype 
Compound Subunit  Subunit  
6-prenylnaringenin Phe156 Glu155, Tyr157 
8-prenylnaringenin Phe46 Arg207, Glu155, Tyr157 
Xanthohumol Arg173, Asp44, Phe46 Glu155, Tyr157 
Isoxanthohumol Arg207, Phe46, Tyr157 Glu155, Tyr157 
Bicuculline Phe46, Phe65 Glu155, Phe200, Tyr157, Tyr205 The residues that are predicted to form strong interactions with prenylflavonoids in the 
binding site between  and  subunits at the  receptor subtype, were 
phenylalanine 46 ( subunit) and glutamine 155 and tyrosine 157 ( subunit). 
2.6. The binding sites receptor model and the full receptor model of  
GABAAR subtype 
The docking results for the binding sites receptor indicate that XN may have the highest 
affinity towards  and  interfaces. 8PN seemed to have the least favorable scoring 
at the  and  sites, while the docking scores ranked 6PN the best at the pocket 
and the lowest at the  binding site (Table 7).  
Table 7. Docking scores and estimated binding free energies in different binding pockets 
of the binding sites receptor model (). 
Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
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6-prenylnaringenin -35.18 -4.291 
8-prenylnaringenin -37.94 -4.500 
Xanthohumol -62.16 -6.787 
Isoxanthohumol -44.98 -5.234 
 
Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -58.79 -8.826 
8-prenylnaringenin -42.56 -4.122 
Xanthohumol -51.83 -6.120 
Isoxanthohumol -49.32 -4.207 
 
Binding site −+ 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -59.97 -8.264 
8-prenylnaringenin -52.50 -7.577 
Xanthohumol -72.15 -9.391 
Isoxanthohumol -59.71 -7.782 
 
The full receptor model results were significantly inferior compared to those of the 
binding sites model. The only compound that had the same ranking at the binding pockets 
was 8PN, however scoring was notably different. Best docking values were obtained at 
  and  for 6PN, XN and IXN, respectively. XN seemed to have the lowest 
affinity at the  binding site (Table 8). 
Table 8. Docking scores and estimated binding free energies in different binding pockets 
of the full receptor model (). 
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Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -35.18 -4.291 
8-prenylnaringenin -40.13 -4.949 
Xanthohumol -30.86 -4.747 
Isoxanthohumol -39.95 -5.452 
 
Binding site +− 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -44.95 -4.895 
8-prenylnaringenin -35.06 -5.602 
Xanthohumol -50.94 -6.779 
Isoxanthohumol -40.37 -4.850 
 
Binding site −+ 
Ligand Prime MMGBSA 
ΔGbind (kcal/mol) Induced fit docking g-score 
6-prenylnaringenin -55.73 -6.510 
8-prenylnaringenin -41.27 -6.306 
Xanthohumol -46.42 -5.846 
Isoxanthohumol -55.11 -6.675 
The values from the full receptor model and the binding sites model were notably lower 
compared to the values in the crystal structures and are considered unreliable. Due to this 
the interacting residues in the studied binding pockets of these two structures were not 
analyzed. 
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3. Discussion 
3.1. Flumazenil/BZD binding site (α1γ2) 
Experimental data has shown that the modulatory action of prenylated flavonoids is 
flumazenil insensitive (Hall et al., 2004; Benkherouf et al., 2019). Hence, the good 
docking scores (comparable or slightly better than those of flumazenil) of hops 
compounds were unexpected. Nonetheless, there is some evidence that flavonoids could 
act the flumazenil-sensitive sire as well (Johnston et al., 2015). It should be kept in mind 
that the docking is done by an algorithm that optimizes the ligand interactions with the 
receptor and cannot be fully relied on. Furthermore, prenylated flavonoids were shown to 
act as allosteric modulators (Benkherouf et al., 2019) on GABAAR, which means that the 
presence of the neurotransmitter GABA is required for the hops exert their action on the 
receptor. For simplicity’s sake, all docking studies were carried out on a receptor 
structure/model that did not have GABA present, as its presence would make MD 
simulations longer and more complex. Only the  and  GABAAR crystals 
(6D6U, 6HUK, respectively) contain GABA but it was removed before docking. 
Based on receptor-based pharmacophore models it may be possible to explain the good 
scores of the hops compounds at the flumazenil/BZD binding site. Richter et al., 2012, 
and Bergman et al., 2013, reported several residues as important for interacting with 
ligands at the BZD site. For example, His101 (His102 in our study) in the  subunit as a 
positively charged amino acid and Phe99 (Phe100) and Tyr159 (Tyr160) that also are part 
of this subunit as hydrophobic interaction points were proposed to be involved in 
interacting with ligands. In  subunit, Phe77 was reported as important hydrophobic 
determinant for the binding of ligands. These residues are also noted as important ligand-
interacting amino acids in this modeling study. These residues are likely to be involved 
in flavonoid binding, as some of the flavonoids’ effects are thought to be a result of 
interacting with the BZD binding site (de Oliveira et al., 2018). For ligands to bind at the 
benzodiazepine site it is necessary that they possess at least two hydrogen bond donating 
moieties and one moiety that would accept a hydrogen bond. The ligands should also  be 
positioned in such a manner that they are able to have lipophilic interactions with a certain 
region of the binding pocket (Clayton et al., 2007).  
A 3D-QSAR flavonoid pharmacophore model proposed by  Huang et al., 2001 identified 
features on 6PN that contribute to its good binding at the  site. 6PN carbon atoms at 
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position 6 and 7 (and their substituents) (Figure 10) were shown to be high sensitivity 
sites regarding the affinity towards the BZD site of the receptor. Moreover, the 3D-QSAR 
pharmacophore model proposes two hydrogen bond acceptors, and two hydrophobic sites 
of interaction, which can be observed in our study in the obtained 6PN interaction with 
the binding pocket. Additionally, the conformation of 6PN in our study corresponds 
to those predicted from 38 structures as a possible binding conformation, in the same 3D-
QSARstudy done by Huang et al., 2001 (Figure 11). It should be noted that their unified 
pharmacophore model did not account for flavanones, which differ in structure from  
flavones as there is no double bond present between the carbon atoms C2 and C3. This 
double bond is assumed to be important for the planarity of the structures and binding to 
the classical BZD site although there are still discrepancies with regard to the structure 
for the pharmacophore model of flavonoids (Dekermendjian et al., 1999; Hall et al., 
2005). 
 
 
 
 
 
Figure 10. Numbering of the carbon atoms in 6-prenylnaringenin and other 
prenylflavonoids. Hydroxyl group is present at position 7 and prenyl group at position 6. 
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Figure 11. Huang et al.’s (2001) pharmacophore hypothesis model of 6PN in  binding 
pocket of GABAAR regenerated by us with the Phase tool in Maestro. Carbon atoms of 
6PN are colored grey, hydrogen atoms are displayed in white and oxygen atoms are 
shown in red. The red arrows point out the acceptor atoms, and orange rings are placed at 
the aromatic ring centers of 6PN. The two hydrophobic groups proposed by Huang et al’s 
3D-QSAR model are marked with the black lines. 
Compared to other hops compounds studied in this project 6PN is the only one with a 
substituent at position 6. This site was speculated to be the one where either hydrogen 
bond or electrostatic interactions occur between ligands and the binding site residues 
(Huang et al., 2001). Figure 12 shows the 2D interactions between the residues located in 
the pocket and the docked 6PN. 
 
Figure 12. 2D representation of the ligand-receptor interactions of the docked 6PN at the 
 pocket in GABAAR. The conformation of both receptor and ligand enables for the 
high amount of hydrogen bonds (purple arrows) and a − stacking interaction between 
the phenyl ring of 6PN and Tyr210 of the  subunit. 
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The residues that interact with the studied compounds are consistent with those obtained 
from the experimental data to be important for binding of agonists at the  pocket of 
GABAAR; tyrosine 210, threonine 142 (of  subunit) and phenylalanine 77of  subunit 
(Buhr et al., 1996; Jursky et al., 2000) Furthermore, a −rich domain in the extracellular 
domain of GABAAR was described in the progressive deletion experiments (Xue et al., 
1999, 2000). Some of the most significant ligand binding residues belong to this domain, 
such as tyrosine 161 (Tyr160 in our study), threonine 162, glycine 200 and threonine 206 
(Thr207 in our study), and they are part of the  subunit. The docked 6PN at the 
 pocket interacts closely with some of those residues (Figure 13). 
 
Figure 13. 6-prenylnaringenin interactions at the α1/γ2 binding site of the GABAA receptor 
isoform  (PDB ID: 6D6U; light pink, cartoon and lines representation). Carbon 
atoms of 6-prenylnaringenin are colored in cyan, oxygen atoms in red and hydrogen 
atoms in white. Residues that form hydrogen bonds with 6-prenylnaringenin are colored 
in magenta and π-π stacking residues are colored in green. The most important 
interactions are π-π stacking interactions between the aromatic ring of 6-prenylnaringenin 
and tyrosine 210 and polar (hydrogen bonding) interactions of 6-prenylnaringenin with 
threonine 142, glutamine 189, histidine 102, serine 159, serine 205 and serine 206. Polar 
interactions are shown as dotted yellow lines. 
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3.2. The CGS-9895 binding site binding pocket between α1+/ β2-subunits 
According to the docking results for the binding pocket between the + and − subunits, 
6PN seems to fit best into this pocket. However, all of the prenylflavonoids had 
comparable scores at this pocket. The reference compound CGS-9895, which acts as a 
positive allosteric modulator at the  site (Varagic et al., 2013) exhibited the highest 
MMGBSA binding energy. Point mutations at the  subunit have indicated that tyrosine 
209 (Tyr210 in our study) was the key residue involved in the mode of action of CGS-
9895 (Maldifassi et al., 2016; Ramerstorfer et al., 2011). Even though tyrosine 210 did 
not form interactions such as hydrogen bonds or − stacking with CGS-9895 in our 
docking model, it was a part of the hydrophobic pocket in the binding site (Figure 14). 
 
 
Figure 14. CGS-9895 interactions at the α1/2 binding site of the GABAA receptor isoform 
 (PDB ID: 6D6U; light pink, cartoon and lines representation). Carbon atoms of 
CGS-9895 are colored in cyan, oxygen atoms in red, nitrogen atoms in blue and hydrogen 
atoms in white. Carbon atoms of residues that form hydrogen bonds with CGS-9895 are 
colored in magenta and carbon atoms of residues involved in π-π stacking or hydrophobic 
interactions are colored in green and white, respectively. The most important interactions 
are π-π stacking interactions between the aromatic rings of CGS-9895and tyrosine 62 and 
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polar interactions (hydrogen bonding) with histidine 102 and serine 206. Polar 
interactions are shown as dotted yellow lines. 
As seen in Table 3, the most important residues interacting with the docked ligands at this 
binding pocket were tyrosine 210, histidine 102, lysine 156 and phenylalanine 100 ( 
subunit). As mentioned earlier, these residues are important for binding of agonists at the 
GABAAR. Figure 15 shows 8PN interactions in this binding pocket. 
 
Figure 15.  8-prenylnaringenin interactions at the α1/2 binding site of the GABAA 
receptor isoform  (PDB ID: 6D6U; light pink, cartoon and lines representation). 
Carbon atoms of 8-prenylnaringenin are colored in cyan, oxygen atoms in red and 
hydrogen atoms in white. Residues that form hydrogen bonds with 8-prenylnaringenin 
are colored in magenta and π-π stacking residues are colored in green. The most important 
interactions are π-π stacking interactions between the aromatic rings of 8-
prenylnaringenin and phenylalanine 100 and tyrosine 62 and polar interactions (hydrogen 
bonding) with histidine 102 and lysine 156. Polar interactions are shown as dotted yellow 
lines. 
Based on the docking score results this may be the most likely binding site of all studied 
pockets in this crystal structure, however one should keep in mind that the scoring 
functions can not be fully relied on. 
3.3. 2-/γ2+binding pocket 
Docking scores at the  isoform seem to be the lowest at the  subunit interface 
(Table 1) for 6PN and 8PN but among the best for XN and IXN. The fact that all the 
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tested prenylflavonoids had different interactions with residues at the  subunit may 
indicate that they either have different binding modes at this site or that the site is located 
at a different interface position. Notable at this site is the absence of the histidine 102 
residue from the  subunit that was experimentally determined as important for binding 
of benzodiazepine agonists (Wieland et al., 1992). This could mean that the histidine 
residue affects the binding of allosteric modulators such as prenylflavonoids and thus, 
they may have a preference towards interfaces that contain an  subunit. 
3.4.   receptor subtype 
The docking scores at the crystal structure of  are significantly worse than those at 
 This may result from the fact that the docking site for  structure was 
selected to be the pocket where bicuculline experimentally binds. This pocket is located 
in the extracellular domain between  and  subunits. However, unlike the pockets 
studied in the  structure and the  models, orientation of α and β subunits is 
different. While the experimental binding site of flumazenil and the pseudo-ligand 
binding sites at the  crystal structures are +−, the binding sites of bicuculline are 
−+ Moreover the subunits take such conformations that the chloride channel of the 
receptor remains closed (Masiulis et al., 2019) This could mean that the studied 
prenylflavonoids have higher affinity towards the +− orientation of the subunits and 
this contributes to the assumption that the studied hops compounds act as positive 
allosteric modulators. Furthermore, while the aromatic residues in the −+ pocket, such 
as Phe65 in , Tyr157, Phe200 and Tyr205 in  (αβ chains) form hydrogen-bonding, 
− stacking, −cation and salt bridge interactions with the isoquinoline and phthalide 
rings of bicuculline, these interactions are not established between the pocket residues 
and the hops compounds. For example, Phe200 in  is not in favorable orientation to be 
able to interact with IXN. Aromatic ring of the amino acid seems to be too far (more than 
4.4 Å, which is considered to be optimal for establishing − stacking) from any of the 
rings of IXN. Additionally, the position of the phenylalanine aromatic ring is oriented so 
that it cannot interact with the IXN rings (Figure 16).  
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Figure 16. Predicted binding mode of IXN (top) and experimental binding mode of 
bicuculline (bottom) in the  binding site of the  isoform crystal structure (A 
and B chains; PDB ID 6HUK), respectively. Carbon atoms of IXN and bicuculline are 
colored in magenta and green, respectively. All oxygen atoms are colored in red, nitrogen 
atoms in blue, and all hydrogens are colored in white. The binding site residues have 
carbon atoms colored grey. − and −cation interactions are presented as blue and green 
dashed lines, respectively. Hydrogen bond interactions are shown as yellow dashed lines. 
Interestingly, the docking results for the two identical  binding sites (between chains 
A and B or D and E) are somewhat different, A/B interface resulting into better docking 
scores than the D/E interface. Bicuculline scores were clearly better than those of the 
prenylflavonoids. However, the scores differed somewhat in the two binding sites for 
bicuculline as well.  
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For example, between chains A and B the best scoring (although not very high in any 
case) of hops compounds was calculated for IXN. In contrast, at the D/E interface the 
free energy of binding for IXN was significantly worse. Superimposing the A/B and 
D/E binding sites may explain the differences between the docking scores at these 
identical sites. In the less favorable (D/E) pocket the conformation of the ligand-
receptor complex has lower number of interacting residues with IXN and greater 
number of steric clashes. For example, in the A/B binding pocket IXN has − stacking 
interactions with Phe46 and Tyr147 and hydrogen bond interactions with Arg207. The 
D/E interface showed only hydrogen bond interactions between IXN and Glu155. In 
fact, IXN has a different pose in both sites (Figure 17). In contrast, bicuculline seems to 
have quite similar poses in both pockets, and there are no significant differences 
between the binding pocket residues’ positions. However, minute differences in the 
binding site conformation likely cause the somewhat different binding scores.  
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Figure 17. a)  IXN pose at the  binding pocket between A and B protein chains 
versus between D and E chains at the  GABAAR subtype (PDB ID: 6HUK). A/B 
site residues are colored in green, D/E site residues are colored in red. IXN bound at the 
A/B interface has carbon atoms colored green and IXN at the D/E pocket has carbon 
atoms colored orange; b) bicuculline in A/B (blue) and D/E (purple) binding pockets of 
the GABAAR; c) interactions of IXN with the side chain residues in the D/E (top) and AB 
(bottom) interface. Carbon atoms of IXN are colored cyan, all oxygen atoms are colored 
red and all hydrogens are colored white. Hydrogen bond interactions are shown as yellow 
dashed lines. 
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8PN had clearly lower values than bicuculline, although it was among the top ranked 
compared to other hops compounds (Table 5). Low docking score values for the 
prenylflavonoids may also be resulting from the conformation of the receptor taken after 
bicuculline binding. Bicuculline binding induced the change in conformation of the 
subunits (Masiulis  et al., 2019) and this may be unfavorable for the binding of 
prenylflavonoids. 
Despite the poor scoring, 8PN can fit well into the pocket since it has the two hydrogen 
donors, one hydrogen acceptor and a notable hydrophobic interaction site, and these 
features were proposed to be required for flavonoids to bind successfully at GABAAR 
(Huang et al., 2001; Clayton et al., 2007). This is presented in Figure 18. 
 
 
Figure 18. Simplified pharmacophore hypothesis model of 8PN in  binding pocket 
of GABAAR (PDB ID: 6HUK) done by Phase in Maestro, based on Clayton et al.’s (2007) 
work. Carbon atoms of 8PN are colored grey, hydrogen atoms are displayed in white and 
oxygen atoms are shown in red. The red arrows point out acceptor atoms, and orange 
rings are placed at the aromatic ring centers of 8PN. Blue arrow represents hydrogen 
donor and the green sphere shows a hydrophobic site. 
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3.5. Receptor models of the α6β3δ isoform 
In general, docking scores in the α6β3δ binding sites model and especially the full receptor 
model are significantly worse than those in the crystal structures of the other two isoforms 
(Tables 1, 7, 8). Nonetheless, the best calculated Prime/MMGBSA binding energy of a 
prenylflavonoid was obtained at this receptor subtype. Despite the fact that both the 
models represent the same binding sites, the docking score/binding energy values for the 
same compounds in the same representative sites in these models were different. Most 
notable was XN scoring at the  site; in the binding sites model it had the best values, 
whereas in the full receptor model it was scored as the worst. This can be explained by 
the differences in positions of the residues that form the pocket. There are less steric 
clashes and more favorable interactions between XN and the amino acids at the binding 
sites receptor model (Figure 19). 
Figure 19. XN interactions at the α6/β3 binding sites of the α6δ3δ GABAA receptor isoform 
in the binding sites model (top) and full receptor model (bottom). Carbon atoms of XN 
are colored in cyan, all oxygen atoms are colored in red, nitrogen atoms in blue and all 
hydrogen atoms in white. Residues that form π-π stacking interactions with XN are 
colored in green. Threonine that causes a steric clash with XN has carbon atoms colored 
in orange. Polar interactions are shown as dotted yellow lines. 
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Experimental data has indicated that out of the studied hops compounds 8PN has the 
highest affinity towards the  GABAAR subtype (Benkherouf et al., 2019). 8PN had 
the worst docking score/binding energy values in two out of the three tested binding 
pockets. However, based on the docking scores/binding energies (Table 8), the most 
likely binding site for 8PN and the other prenylflavonoids at this receptor subtype could 
be the  site. Contrary to the experimental data that has shown XN to exhibit the lowest 
binding affinity to GABAAR of the prenylflavonoids (tested on α1β3γ2, α2β3γ2 and α6β3δ 
subtypes, expressed in HEK293 cell line) (Benkherouf et al., 2019), in this project it 
seemed to show the highest affinity towards most of the binding sites where the hops 
compounds were docked. 
Even though the docking scores/binding energy estimates suggest  as the most likely 
binding site for prenylflavonoids at the  GABAAR subtype, other sites may be 
possible too, if the conformation of the side chains would be different. Without an 
experimental structure of the  GABAAR subtype, it is not possible to know exactly 
what the ligand-binding conformation of the residues at the receptor binding sites is. The 
inaccurate conformation is likely the reason why the scores are so low, especially in the 
case of the full receptor model. 
Another important note is that with the used methods and models it is difficult to give any 
definite ligand-receptor affinities as the scoring algorithms are inaccurate and depend 
largely on the binding site conformation (Chen, 2015; Li et al., 2019). Some of the scoring 
functions work well for specific targets but could be incorrect for the others and docking 
poses can be scored well, despite not being the correct ones (Scior et al., 2012; Bauer et 
al., 2013).  
Moreover, if any of the residues in the full receptor model used in this study was 
misaligned, it may have led to a wrong binding site model or misplacement of other 
structurally crucial residues, which then affects the stability of the protein (during the MD 
simulation). This can occur when incorrect alignment causes the orientation or solvent 
accessibility of the residues that make up the active sites to take a false conformation 
(Burke et al., 1999) Even though the models used here were energy minimized and 
equilibrated, such steps do not lead to recovering from alignment  errors (Marti-Renom 
et al., 2000).  
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In summary, the obtained results suggest that prenylflavonoids may bind to more than 
one pocket in the extracellular domain of the studied GABAAR subtypes. It was not 
possible to definitely distinguish high affinity binding sites from low affinity binding sites 
as the docking results varied for each compound in the studied pockets. Furthermore, even 
the same subunits’ interface pockets on the different GABAAR subtypes could be 
different for the same compounds (due to different binding site conformations) as it was 
the case for the full receptor model and the binding sites model of the  GABAAR 
subtype. Molecular modeling approaches can aid in predicting unknown binding sites of 
compounds at their target proteins. However, there are limitations such as inaccurate 
scoring functions and lack in the accuracy of modelling the binding sites. The possible 
occurrence of inadequate and false results may be partly omitted by the use of more 
exhaustive methods such as MD simulations. These methods take into the account the 
flexibility of the receptor. However, in order to determine the binding site and binding 
mode of the prenylated flavonoids most accurately, experimental structure determination 
by X-ray crystallography could be attempted. 
Based on the literature and the data obtained from this project, there are some propositions 
for future studies.  For example, a ligand-binding assay that would include CGS-9895 
could be attempted with the aim to determine if its activity is blocked by the hops 
compounds. As previously discussed, the interface in the ECD of GABAAR that is 
assembled from the +− subunit is positively allosterically modulated by this 
pyrazoloquinoline. This suggests that if hops compounds block or reduce the effects on 
the GABAAR that resulted from this compound, the pocket in which they bind may be 
the same. Furthermore, ligand-binding assays that would include flurazepam might be 
useful as well, since this compound was reported to share the same site of action as CGS-
9895 (ref). However, there are some conflicting experimental data whether the site of 
action is shared between these two compounds (Maldifassi et al., 2016, Ramerstorfer et 
al. 2011). Flurazepam has likely multiple sites of action and recently it was shown to act 
through the  site of the  GABAAR subtype (Jatczak-Śliwa et al., 2018). The 
docking study performed in this project showed this site to be potentially interacting with 
the prenylflavonoids. Thus, assays with flurazepam may yield new insight into the 
location of the exact binding pocket and the subunit preference of hops compounds. 
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4. Required Methodology, Materials and Methods including 
Experimental Design 
4.1.  Protein and ligand structure preparation. 
Protein Data Bank ([PDB]; available at: www.rcsb.org; Berman et al., 2000) was used to 
study the available GABAAR structures complexed with various ligands. The GABAAR 
α1β2γ2 isoform has been crystallized with the known BZD antagonist flumazenil (PDB ID 
6D6U, resolution3.92 Å; Zhu et al., 2018) and GABAAR α1β3γ2isoform with the 
competitive GABAAR antagonist bicuculline (PDB ID 6HUK; resolution 3.69 Å; 
Masiulis et al., 2019).As a template for creating a model of the α6β3δ isoform, a 
homopentameric (β3 subunit) GABAAR was used (PDB ID 4COF; resolution 2.97 Å; 
Miller and Aricescu, 2014). All structures were investigated and visualized using the 
Maestro molecular modelling package (version 2019-1; Schrödinger, LLC) and PyMOL-
visualization tool (The PyMOL Molecular Graphics System, Version 2.3 Schrödinger, 
LLC.).Protein crystal structures were pre-processed with the Protein Preparation Wizard 
of Maestro; missing hydrogens were added and water molecules were removed. All co-
crystallized ligands and glycans that were not needed for the purpose of this study were 
removed. 
Two-dimensional structures of 6PN, 8PN, IXN, XN, bicuculline, flumazenil and 
pyrazoloquinoline 2‐p‐methoxyphenylpyrazolo[4,3‐c]quinolin‐3(5H)‐one (CGS-9895) 
were obtained from PubChem (Kim et al., 2019) and converted to 3D with the LigPrep 
tool of Maestro.CGS-9895 is experimentally determined as ligand that binds at the 
+− pocket in the extracellular part of the receptor. Furthermore, it is shown that 
thetypes of the  and  subunits dictate the type of modulation by the CGS-9598 
(Ramerstorfer et al., 2011). However, the clinical use of this pyrazoloquinoline is limited 
due to low solubility of the compound. Nevertheless, the structure, topology and the 
affinity that this compound has for the GABAAR make it a common template for the 
pharmacophore-receptor models (Huang et al., 2000).Protein structures were pre-
processed with protein preparation wizard of Maestro; water molecules were removed, 
and missing hydrogens were added. All present ligands and glycans that were not needed 
for the purpose of this study were removed prior to preprocessing of the crystal structures. 
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4.2. Homology modeling. 
The receptor subunits that were needed for the study but were not available from the PDB 
were created using the homology (comparative) modeling approach. The modeling 
alignments of the α6 and δ subunits were generated using the multiple sequence alignment 
tool ClustalOmega (available at: www.clustal.org/omega; Sievers et al., 2011). Another 
sequence alignment web tool, EMBOSS Needle (EMBL-EBI), was used for pair wise 
alignments (available at: www.ebi.ac.uk/Tools/psa/emboss_needle; Madeira et al., 2019). 
The actual model building was performed by MODELLER version 9.20 (available at: 
https://salilab.org/modeller, Sali et al., 1993; Webb et al., 2016).  
MODELLER creates comparative protein models by satisfying spatial restrains (Sali and 
Blunder, 1993; Webb and Sali, 2014). The model creation is a step-wise procedure: (i) 
dihedral angle and the distance restraints on the target model are obtained from the 
sequence alignment of the model sequence with the template 3D structure to reach the 
homology-derived restraints; (ii) the spatial restraints are imposed by the use of 
CHARMM22 force field (MacKerell et al., 1998) to obtain an objective function that is 
dependent on the Cartesian coordinates of the modeled molecules; (iii) the final model is 
created by optimizing the objective function in Cartesian space by applying the variable 
target function method (Braun and Go, 1985), using the conjugate gradients approach and 
molecular dynamics with simulated annealing (Clore et al., 1986). 
Protein sequences of the GABAAR subunits α6 and δ were obtained in FASTA format 
from the UniProt Knowledgebase (available at: www.uniprot.org; sequence entries 
Q16445 and O14764, respectively). The Protein BLAST tool (Altschul et al., 1990) was 
used to find similar proteins and consequently the multiple sequence alignment was 
created using the ClustalOmega tool. Crystal structures of GABAAR subunits (from PDB 
IDs: 6D6T and 6A96 and 4COF) were used as templates for the α6 and δ subunits. Crystal 
structure of the homopentameric GABAAR (PDB ID: 4COF) was used as the template 
for the full α6β3δ receptor model. Initial 10 models of each structure were created, and the 
quality ranking was done with the DOPE (Discrete Optimized Protein Energy) score 
(Shen and Sali, 2006) of MODELLER, where the lower energy value means a better 
model.  
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Additionally, a simplified α6β3δ GABAAR binding sites model was created by mutating 
only the binding site residues of α1β22 GABAAR in the 6D6U crystal structure; mutations 
were done based on the pair-wise sequence alignment. Mutated residues at the 
+− binding site were histidine 102 to arginine (His102Arg), serine 206 to asparagine 
(Ser206Asn) (in  subunit), aspartic acid 56 to alanine (Asp56Ala), tyrosine 58 to 
glutamic acid (Tyr58Glu), alanine 79 to histidine (Ala79His), threonine 142 to serine 
(Thr142Ser) (in  subunit). Residue numbers correspond to those of the human α1β2 
GABAAR sequence. The residues at the +− binding pocket that were mutated were 
His102Arg, Ser206Asn (in  subunit). The mutated residues at the −+ binding 
pocket were arginine 114 to valine (Arg114Val), tyrosine 220 to phenylalanine 
(Tyr220Phe), threonine 215 to lysine (Thr215Lys), threonine 216 to serine (Thr216Ser) 
and serine 217 to alanine (Ser217Ala) (in  subunit).  
4.3. Molecular dynamics (MD) simulations. 
MD simulations were carried out to study the conformational space at the subunit 
interfaces by the molecular simulation package Amber 18 (Salomon‐Ferrer, Case et al. 
2013). Amber's primary protein force field, the ff14SB (Maier et al., 2015), was used to 
perform the minimization and simulations of the proteins and the tleap program was used 
to solvate the proteins and generate the input topology and coordinates of the structures. 
An octahedral box was selected as the most suitable for all the MD simulations, based on 
the lowest number of waters present. The octahedral box that extended 10 Å around the 
protein. Neutralization of the simulation system for the  full receptor model was 
done with Na+ counter ions, whereas the system for the binding sites model was 
neutralized with Cl- ions. The initial minimization was carried out in 6 steps (each step 
200 iterations) using two algorithms, steepest descent (for the first 10 iterations) and 
conjugate gradient (the last 190 iterations), so that the restraint force on the proteins was 
slowly reduced from 10 to 0 kcal/molÅ2. Likewise, equilibration of the simulation system 
was performed stepwise: (i) by the use of the Langevin dynamics, the system was heated 
for 10 ps, starting at 10 K until it reached 300 K (frequency of collision was γ=1.0ps-1), 
keeping the constant volume with the fixed protein and the restraint force of 5kcal/ molÅ2; 
(ii) 20 ps heating from 10 K to 300K with the Langevin dynamics, without restraint 
constraints on the protein; (iii) 20 ps at constant temperature (300 K) and 
volume(Langevin dynamics and frequency of collision γ=0.5ps-1) and with no constraints 
applied; (iv) 50 ps at 300K at constant pressure of 1 bar with 1 ps coupling constant and 
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no restraints; (v) 400 ps equilibration in the same conditions as the production simulation 
constant. The production simulations for the minimized and equilibrated structures were 
carried out for 25 ns at 300 K and at 1 bar pressure. SHAKE algorithm, which constraints 
all the bonds that include hydrogen (Elber et al., 2011), was used with the time step of 2 
fs. The coupling constants to the pressure and temperature baths were 2 ps and 5 ps, 
respectively. The final structure frame after the simulation was minimized for 200 (10 
steepest descent + 190 conjugate gradient) iterations with no restraints on the protein. MD 
trajectories were visualized with Visual Molecular Dynamics (VMD), molecular graphics 
program (Humphrey et al., 1996). 
To avoid affecting the docking site conformations more than necessary, minimized and 
equilibrated structure of the α6β3δ binding sites model was used for further docking 
studies. Ramachandran plot assessment was performed by the use of RAMPAGE (Lovell 
et al., 2003) to evaluate the stereo-chemical quality of the final structures of the receptor 
models before and after MD. Evaluation with the Ramachandran plot provides an 
overview of how the torsion angles in a protein are distributed and which angle regions 
are excluded because of steric hindrance. These torsion angles in the protein sequence are 
termed Phi (φ) and Psi (ψ). The former describes the protein backbone rotation around 
the nitrogen and the alpha carbon (C) bonds, whereas the latter describes the backbone 
rotation around C and C (carbonyl carbon) bond. The torsion angles belong to principal 
parameters that determine protein folding and the flexibility that is needed for a protein 
backbone to take a certain conformation (Morris et al., 1992). Moreover, in high quality 
experimental structures and protein models, all or most of the phi/psi angles are within 
the standard values depicted by the Ramachandran plot. 
CPU expensive calculations such as MD and were performed at the supercomputers of CSC, the Finnish IT Center for Science. 
4.4.  Docking. 
Docking of the hops compounds and the reference compounds flumazenil, bicuculline 
and CGS-9895 to the GABAAR crystal structures (PDB ID: 6D6U, 6HUK) and models 
was performed with the GLIDE tool of the Maestro package (Friesner et al., 2004) using 
the extra precision algorithm (XP). The Glide XP algorithm uses the empirical scoring 
function that favors lipophilic contacts in an atom-atom pair score between a protein and 
a ligand, hydrogen bonds within a protein-ligand complex and gives an entropic penalty 
depending on the amount of present rotatable bonds within the ligands. Furthermore, this 
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algorithm uses desolvation penalties if charged or polar groups from ligand or protein are 
buried. Another crucial implementation to the XP algorithm is that it recognizes specific 
molecular motifs that largely contribute to the increased binding affinity (Friesner et al., 
2006). In addition, docking at the two suggested putative binding sites, located at the 
+− and −+ of α1β22 GABAAR crystal structure (PDB ID: 6D6U) (Zhu et al., 
2018) was carried out with the Induced Fit protocol of Maestro.  
Free energy of binding for the receptor-ligand complexes was calculated with the 
Prime/MMGBSA (molecular mechanics–generalized Born surface area) tool of Maestro 
(Jacobson et al., 2002, 2004). VSGB2.1 solvation model (Li et al., 2011) was used with 
the OPLS3 force field (Optimized Potentials for Liquid Simulations) in order to gain the 
higher accuracy in the calculations of the free binding energy between the receptor and 
the ligands. The free energy of binding is calculated with the MMGBSA method by 
employing the following equations: (i)∆Gbind =Gcomplex-Greceptor–Gligand; (ii) ∆Gbind = ∆H-
T∆S ≈ ∆Egas +∆Gsol -T∆S; (iii) ∆Egas = ∆Eint +∆EELE +∆EVDW; (iv) ∆Gsol = ∆GGB + ∆GSurf. 
∆Gbind represents the free energy of binding and is further divided into different energy 
types. ∆Eint represents the internal energy charge, however, as the trajectories for the 
receptor-ligand structure that belong to the protein and the ligand are the same, this energy 
is dismissed. ∆Egas - the energy of interaction of the ligand and the receptor in the gas 
phase is calculated as the sum of ∆EELE - the electrostatic energy, and ∆EVDW - van der 
Waals energy. ∆Gsol is the free energy of solvation, that is further separated into the non-
polar and polar energies. GGB – describes the polar energy of solvation and the generalized 
Born surface area model is used for its determination. The value of the non-polar solvation 
energy is calculated based on the surface area that is accessible by solvent. ∆GSurf 
represents the surface area accessible by the solvent and is used to determine the non-
polar energy (Zhang et al., 2017). Docking scores and energy values were used in ranking 
the ligands and docking poses, with a lower score meaning better affinity. 
The hops compounds and flumazenil were docked at the +− site (the experimental 
flumazenil binding site) and the +−  −+ binding pockets of the α1β22 
GABAAR crystal structure (PDB ID: 6D6U). Additionally, CGS-9895 was docked at the 
+− pocket. The +− binding site is formed by Phe100, His102, Tyr160, Ser205, 
Ser206, Thr207, Tyr210 ( subunit) and Tyr58, Phe77, Ala79, Thr142 ( subunit). 
Residues that form the +− pocket are Phe100, His102, Tyr160, Ser205, Ser206, 
Thr207, Tyr210 ( subunit) and Asp43, Tyr62, Gln64 ( subunit). The −+ binding 
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pocket residues are Asp43, Tyr62, Gln64 ( subunit) and Phe112, Arg114, Tyr72, 
Thr215, Thr217, Ser217 ( subunit). The docking site was defined as the centroid of the 
selected residues with the maximum length of the docked ligands set to 20 Å. The 
+− and −+ binding site residues at the α1β22 isoform structure were selected 
based on the article by Zhu et al. (2018). In the α6β3δ isoform binding sites model as well 
as the full receptor model the ligands were docked at the same sites as in the α1β22 crystal 
structure (Figure 17). Another two docking sites that were probed were the two −+ 
sites of the α1β3γ2 isoform crystal structure (PDB ID: 6HUK) (Figure 20). They are the 
experimentally determined binding pockets of bicuculline (ref). The co-crystallized 
bicuculline was set as the centroid for the docking pocket and maximum size of the 
docked ligands was limited to 20 Å. 
 
Figure 20. Docking sites at the crystal structures of  (left) and  (right) crystal 
receptor structures (PDB ID: 6D6U, 6HUK, respectively) denoted by the surface 
presentation of the binding site residues.  
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6. List of abbreviations 
6PN  6-prenylnaringenin 
8PN  8-prenylnaringenin 
Ala  Alanine 
Arg  Arginine 
Asp   Aspartic acid 
BZD  Benzodiazepine  
Cl-  Chloride ion 
CNS  Central nervous system 
D/E  Chains D/E interface 
ECD  Extracellular domain 
GABA  γ-amino butyric acid 
GABAAR  γ-amino butyric acid receptor, class A 
GABAARs  γ-amino butyric acid receptorS, class A 
Glu  Glutamic acid 
His   Histidine  
IXN  Isoxanthohumol 
Leu  Leucine 
Lys  Lysine 
MD  Molecular dynamics 
MMGBSA  Molecular Mechanics Generalized Born Surface Area 
PDB  Protein Data Bank 
Phe  Phenylalanine  
Ser   Serine  
Thr  Threonine  
Tyr   Tyrosine  
VMD  Visual Molecular Dynamics 
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XN 
 
 Xanthohumol   
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8.Appendix 
Graphical and alignment representations of the BLAST similarity search results for the 
GABAAR subunits  and  a) and b), respectively. 
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